Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m

 
• By Lucie Ellis-Taitt
  
Big Fish
Lundbeck acquires Prexton for novel Phase II Parkinson's disease drug • Source: Shutterstock

More from Deals

More from Business